VEVYE
Peakcyclosporine ophthalmic solution
NDAOPHTHALMICSOLUTION
Approved
May 2023
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
VEVYE (cyclosporine ophthalmic solution) is calcineurin inhibitors [moa]. First approved in 2023.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VEVYE is a cyclosporine ophthalmic solution approved in May 2023 for treating dry eye disease by suppressing local immune-mediated inflammation via calcineurin inhibition. It is administered as an eye drop and represents a novel formulation of a well-established immunosuppressant mechanism adapted for ocular surface disease. The drug targets patients with moderate-to-severe dry eye who have not adequately responded to conventional therapies.
Peak15.7 years to LOE
Early peak-stage product with long patent protection suggests stable commercial team and sustained investment in market development and patient access programs.
Mechanism of Action
Calcineurin Inhibitors
Pharmacologic Class:
Calcineurin Inhibitor Immunosuppressant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VEVYE offers mid-career professionals a rare opportunity to drive growth in a newly approved, well-differentiated therapeutic space with minimal competition and robust patent protection through 2042. Commercial, medical affairs, and market access roles will be critical as the brand matures from launch phase into market consolidation.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.